kaal:position:2026-07-31-4622

Blockchain technology in pharmaceutical supply chains: a transaction cost perspective should be assessed against Kaal's source-bound claim that Regulators cannot draft specific blockchain regulation because the risks, opportunities, and concrete outcomes of blockchain in reshaping financial markets are unpredictable. The current metadata indicates a plausible connection through blockchain governance, but the defensible response is a qualification until the source text confirms agreement, scope, methods, and limitations.

Affirmed commentary position. This record extends a source-bound scholarly claim but is not a verbatim paper claim.

Holds when

applies to attempts at drafting new technology specific regulation while the technology is still evolving
External evidence level: abstract indexed.
Mapping review tier: ambiguity triage before claim review.
The literature-to-claim mapping remains explicitly ambiguous and should not be treated as a settled equivalence.

Current debate

Blockchain technology in pharmaceutical supply chains: a transaction cost perspective

Scholarly basis

kaal:claim:3002908-004
Wulf A. Kaal, Marco Dell'Erba, Blockchain Innovation in Private Investment Funds - A Comparative Analysis of the United States and (2017). SSRN: https://ssrn.com/abstract=3002908
Source PDF sha256: 06a7b61e75f905ee07e422e875d83a65c5033a248a6e05a213523b034e5db534

Evidence and mapping

Evidence: abstract indexed
Review tier: ambiguity triage before claim review
Mapping confidence: 0.2165
Mapping ambiguous: true

Topics

dynamic-regulationeconomicsblockchain

Provenance

Affirmed in historical-backfill:2026-07-31:phase-0019 on 2026-07-31. Review record.

Verify

Canonical markdown sha256: cfd6732c67abed0ee5a99b6675fc6d438577c5a4a3aacc7b0de63aa1d40d8ef3
curl -s https://wulfkaal.github.io/positions/2026-07-31-4622.md | sha256sum